Johnson & Johnson
JNJJohnson & Johnson (JNJ) is a multinational healthcare company known for its diversified portfolio of pharmaceuticals, medical devices, and consumer health products. Founded in 1886, it has established itself as a leading player in healthcare, with a global presence and a reputation for innovation and quality in the industry.
Dividend History
Investors can expect a dividend payout of $1.30 per share, scheduled to be distributed in 63 days on March 10, 2026
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| March 10, 2026 | $1.30 | 2026-02-24 | 2026-02-24 |
| December 9, 2025 | $1.30 | 2025-11-25 | 2025-11-25 |
| September 9, 2025 | $1.30 | 2025-08-26 | 2025-08-26 |
| June 10, 2025 | $1.30 | 2025-05-27 | 2025-05-27 |
| March 4, 2025 | $1.24 | 2025-02-18 | 2025-02-18 |
Dividends Summary
- Johnson & Johnson has issued 89 dividend payments over the past 22 years
- The most recent dividend was paid 28 days ago, on December 9, 2025
- The highest dividend payed out to investors during this period was $1.30 per share
- The average dividend paid during this period was $0.75 per share.
Company News
Coca-Cola, Kimberly-Clark, and Johnson & Johnson are recommended as Dividend Kings with 50+ years of consecutive dividend increases. These companies offer high-yielding dividends (2.5%-5%), strong financial profiles, and growth prospects through organic expansion and strategic acquisitions, making them suitable for passive income investors in 202...
Pfizer is investing heavily in the obesity drug market through a $2.1 billion licensing deal with YaoPharma, hoping to recover revenue lost from declining COVID-19 vaccine sales and improve its struggling stock performance.
Johnson & Johnson received an FDA priority voucher for Tecvayli, a multiple myeloma treatment. Bank of America raised its price target to $220 but noted limited pipeline catalysts and modest near-term launch expectations for key drugs.
The global adhesive bandages market is expected to grow to $4.48 billion by 2032, driven by rising minor injuries, increased healthcare awareness, and product innovations, despite challenges like skin irritation and pricing pressures.
This week, J&J and Novartis reported strong Q2 earnings, while Roche's investigational oral weight loss drug showed positive results in an early-stage study. AbbVie also filed for approval of its drug Rinvoq for a new indication.
